This company has been marked as potentially delisted and may not be actively trading. TenX Keane Acquisition (TENK) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsOwnershipTrendsBuy This Stock TENK vs. IKT, FTLF, ALTS, FATE, NMRA, IMRX, NKTX, RAPT, GLSI, and ACTUShould you be buying TenX Keane Acquisition stock or one of its competitors? The main competitors of TenX Keane Acquisition include Inhibikase Therapeutics (IKT), FitLife Brands (FTLF), ALT5 Sigma (ALTS), Fate Therapeutics (FATE), Neumora Therapeutics (NMRA), Immuneering (IMRX), Nkarta (NKTX), Rapt Therapeutics (RAPT), Greenwich LifeSciences (GLSI), and Actuate Therapeutics (ACTU). These companies are all part of the "pharmaceutical products" industry. TenX Keane Acquisition vs. Its Competitors Inhibikase Therapeutics FitLife Brands ALT5 Sigma Fate Therapeutics Neumora Therapeutics Immuneering Nkarta Rapt Therapeutics Greenwich LifeSciences Actuate Therapeutics Inhibikase Therapeutics (NYSE:IKT) and TenX Keane Acquisition (NASDAQ:TENK) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership. Does the media favor IKT or TENK? In the previous week, Inhibikase Therapeutics' average media sentiment score of 0.37 beat TenX Keane Acquisition's score of 0.00 indicating that Inhibikase Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Inhibikase Therapeutics Neutral TenX Keane Acquisition Neutral Do analysts recommend IKT or TENK? Inhibikase Therapeutics presently has a consensus target price of $6.50, suggesting a potential upside of 225.00%. Given Inhibikase Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Inhibikase Therapeutics is more favorable than TenX Keane Acquisition.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inhibikase Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50TenX Keane Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has preferable valuation and earnings, IKT or TENK? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInhibikase TherapeuticsN/AN/A-$19.03M-$2.67-0.75TenX Keane AcquisitionN/AN/AN/AN/AN/A Is IKT or TENK more profitable? TenX Keane Acquisition's return on equity of 0.00% beat Inhibikase Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Inhibikase TherapeuticsN/A -350.63% -201.82% TenX Keane Acquisition N/A N/A N/A Do insiders & institutionals hold more shares of IKT or TENK? 3.8% of Inhibikase Therapeutics shares are owned by institutional investors. Comparatively, 70.5% of TenX Keane Acquisition shares are owned by institutional investors. 7.3% of Inhibikase Therapeutics shares are owned by insiders. Comparatively, 22.9% of TenX Keane Acquisition shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. SummaryInhibikase Therapeutics and TenX Keane Acquisition tied by winning 4 of the 8 factors compared between the two stocks. Get TenX Keane Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for TENK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TENK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TENK vs. The Competition Export to ExcelMetricTenX Keane AcquisitionHolding Offices Industry SectorNASDAQ ExchangeMarket Cap$28.87M$178.65M$2.01B$9.02BDividend YieldN/A5.38%13.70%4.03%P/E RatioN/A2.4812.2420.14Price / SalesN/A412.692,671,752.63184.49Price / CashN/A74.7861.1357.97Price / BookN/A6.153.265.60Net IncomeN/A$3.67M-$462.58M$248.50M TenX Keane Acquisition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TENKTenX Keane AcquisitionN/A$4.34+1.9%N/A-62.5%$28.87MN/A0.00N/AGap UpHigh Trading VolumeIKTInhibikase Therapeutics1.2648 of 5 stars$1.85-5.1%$6.50+251.4%+51.2%$137.53M$260K-0.696FTLFFitLife Brands4.0501 of 5 stars$13.61-3.7%$20.50+50.6%-17.9%$132.79M$64.47M16.2020News CoverageALTSALT5 Sigma0.0642 of 5 stars$7.88+4.1%N/AN/A$132.04M$12.53M0.00170FATEFate Therapeutics4.2835 of 5 stars$1.12-1.8%$3.83+242.3%-63.3%$130.65M$13.63M-0.75550Gap DownNMRANeumora Therapeutics2.1554 of 5 stars$0.78-1.8%$9.29+1,087.1%-90.1%$128.80MN/A-0.49108News CoverageIMRXImmuneering4.0525 of 5 stars$3.59+4.4%$13.25+269.1%+300.9%$123.79M$320K-1.8360Positive NewsNKTXNkarta2.3608 of 5 stars$1.74+1.8%$14.33+723.8%-68.4%$121.34MN/A-1.15140RAPTRapt Therapeutics4.4069 of 5 stars$8.01+9.3%$24.00+199.6%-67.2%$121.21M$1.53M-0.4280Analyst ForecastGLSIGreenwich LifeSciences1.5081 of 5 stars$9.88+9.2%$39.00+294.7%-32.0%$120.98MN/A-7.843ACTUActuate Therapeutics1.9766 of 5 stars$6.74+10.0%$20.50+204.2%N/A$120.27MN/A0.0010High Trading Volume Related Companies and Tools Related Companies IKT Alternatives FTLF Alternatives ALTS Alternatives FATE Alternatives NMRA Alternatives IMRX Alternatives NKTX Alternatives RAPT Alternatives GLSI Alternatives ACTU Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TENK) was last updated on 7/10/2025 by MarketBeat.com Staff From Our PartnersGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredHow a Kansas farm boy gained 1,285% in two daysA former farm kid placed a simple trade… and cashed out a 1,285% gain two days later. It wasn’t crypto or a...TradeSmith | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TenX Keane Acquisition Please log in to your account or sign up in order to add this asset to your watchlist. Share TenX Keane Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TENK Stock Alerts